Results 91 to 100 of about 42,220 (210)

Losartan Ameliorates Calcium Oxalate-Induced Elevation of Stone-Related Proteins in Renal Tubular Cells by Inhibiting NADPH Oxidase and Oxidative Stress

Oxidative Medicine and Cellular Longevity, 2018
Calcium oxalate (CaOx) is the most common type of urinary stone. Increase of ROS and NADPH oxidase gives rise to inflammation and injury of renal tubular cells, which promotes CaOx stone formation.
Baolong Qin, Qing Wang, Yuchao Lu, Cong Li, Henglong Hu, Jiaqiao Zhang, Yufeng Wang, Jianning Zhu, Yunpeng Zhu, Y. Xun, Shaogang Wang   +10 more
semanticscholar   +1 more source

Measurement and management of adult blood pressure in the peri‐operative period: updated guidelines from the Association of Anaesthetists and the British and Irish Hypertension Society

Anaesthesia, Volume 81, Issue 3, Page 402-414, March 2026.
Summary Introduction Maintaining stable blood pressure during surgery is a key responsibility of anaesthetists. Peri‐operative omission and reintroduction of antihypertensive drugs, general anaesthesia, neuraxial and regional techniques can all cause significant fluctuations in blood pressure, particularly in patients with hypertension. Since the first
Terry McCormack, Alex Wickham, Sinéad T. J. McDonagh, Matthew D. Wiles, Luca Faconti, Rachael Brooks, Simon G. Anderson, Andrew Hartle   +7 more
wiley   +1 more source

MODERN POSSIBILITIES OF ACHIEVING TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS IN OUTPATIENT PRACTICE: THE LEADER STUDY RESULTS

Рациональная фармакотерапия в кардиологии, 2018
Aim. To study the efficacy and safety of the use of hydrochlorothiazide/losartan or amlodipine/losartan fixed combinations in patients with arterial hypertension (HT) in real clinical practice.Material and methods.
D. V. Nebieridze, A. S. Safaryan, V. A. Vygodin, O. M. Drapkina, S. A. Boytsov   +4 more
doaj   +1 more source

Klotho and PPAR Gamma Activation Mediate the Renoprotective Effect of Losartan in the 5/6 Nephrectomy Model

Frontiers in Physiology, 2018
Renin angiotensin system (RAS) blockade reduces the progression of chronic kidney disease (CKD) independently of its antihypertensive effect. Ang II-induced fibrosis can be mediated by molecules such as klotho, peroxisome proliferator-activate receptor γ
E. Maquigussa, J. Paterno, Gabriel H. de Oliveira Pokorny, Mariana da Silva Perez, V. Varela, Antônio da Silva Novaes, N. Schor, M. Boim   +7 more
semanticscholar   +1 more source

Modifiable Risk Factors in Atrial Fibrillation: Clinical Implications and Pathophysiological Insights

Annals of Noninvasive Electrocardiology, Volume 31, Issue 2, March 2026.
Modifiable cardiometabolic and lifestyle factors converge on shared atrial mechanisms, including fibrosis, autonomic imbalance, and electrical remodeling, to promote AF initiation and recurrence. Targeting these upstream drivers through structured risk‐factor management enhances rhythm‐control durability and improves long‐term clinical outcomes ...
Chamath Jagoda
wiley   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, Volume 74, Issue 3, Page 636-647, March 2026.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

International Journal of Nephrology and Renovascular Disease, 2010
Elizabeth Ripley, Ari HirschDivision of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USAAbstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago.During those years, researchers and clinicians have ...
Elizabeth Ripley, Ari Hirsch
doaj  

Modeling the Influence of CYP2C9 and ABCB1 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Losartan

Pharmaceutics
Background/Objectives: Hypertension is a pathological condition characterized by elevated systolic and/or diastolic blood pressure. A range of pharmacotherapeutic agents are available to treat this condition and prevent complications, including the ...
Dmitry Babaev, Elena Kutumova, Fedor Kolpakov   +2 more
doaj   +1 more source

Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension

Кардиоваскулярная терапия и профилактика, 2011
Aim. To assess the potential of the angiotensin II receptor antagonist losartan for the correction of hyperuricemia (HU) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods.
S. V. Nedogoda, E. V. Chumachok, A. A. Ledyaeva, V. V. Tsoma   +3 more
doaj   +1 more source